Skip to main content
Year archive

Ascentage Pharma Group International — 2020 filings

All 57 regulatory filings released by Ascentage Pharma Group International (6855) in 2020, sourced directly from the official regulator.

57 Filings
2020 Period
2020 filings (57)
Filing Released Lang
Voluntary Announcement - Received milestone payment for the partnership with UNITY Biotechnology
Capital/Financing Update
2020-12-22 English
Voluntary Announcement - Announcement of updates on the clinical development of APG-2575, including an objective response rate of 70% in patients with relapsed/refractory Chronic Lymphocytic Leuk
Regulatory Filings
2020-12-10 English
Voluntary Announcement - Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) was announced at 2020 American Society of Hematology Annual Meeting
Regulatory Filings
2020-12-08 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2020-12-04 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF MR. GANG ZHU AS CHIEF COMMERCIAL OFFICER
Board/Management Information
2020-12-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Share Issue/Capital Change
2020-12-03 English
Voluntary Announcement - Phase IIa clinical study of APG-115 as single agent or in combination with APG-2575 receives clearances in China and the U.S.
Regulatory Filings
2020-12-02 English
CLARIFICATION ANNOUNCEMENT
Regulatory Filings
2020-11-30 English
Voluntary Announcement - Entry into of an agreement with the University of Michigan to obtain an exclusive license for a MDM2 Protein Degrader using PROTACs Technology
Regulatory Filings
2020-11-30 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2020-11-25 English
Voluntary Announcement - APG-2575 completed dosing of the first patient in Europe in Phase Ib/II clinical study
Capital/Financing Update
2020-11-25 English
Voluntary Announcement - APG-2575 Receives Approvals for Two Phase Ib/II Clinical Studies in China
Regulatory Filings
2020-11-23 English
Voluntary Announcement - Ascentage Pharma Accepted for the Third Time to Release Updated Clinical Data of HQP1351 (Olverembatinib) in Drug-Resistant Chronic Myeloid Leukemia in an Oral Presentation at
Regulatory Filings
2020-11-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020
Regulatory Filings
2020-11-04 English
Voluntary Announcement APG-115 Granted Approval for the Phase Ib/II Clinical Study in China
Regulatory Filings
2020-10-27 English
Voluntary Announcement - Olverembatinib (HQP1351) of Ascentage Pharma is included in the list of "Priority Review"
Regulatory Filings
2020-10-21 English
Voluntary Announcement - APG-115 and APG-1252 Granted Orphan Drug Designation by the US FDA
Regulatory Filings
2020-10-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020
Regulatory Filings
2020-10-07 English
GRANT OF AWARDS UNDER THE RSU SCHEME
Transaction in Own Shares
2020-09-16 English
Voluntary Announcement - APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer
Regulatory Filings
2020-09-14 English
INTERIM REPORT 2020
Interim / Quarterly Report
2020-09-14 English
Voluntary Announcement - APG-2575 Granted Second Orphan Drug Designation by the US FDA
Regulatory Filings
2020-09-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020
Capital/Financing Update
2020-09-03 English
ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2020
Interim / Quarterly Report
2020-08-18 English
VOLUNTARY ANNOUNCEMENT - BECOMING A CONSTITUENT OF THE HANG SENG FAMILY OF INDEXES
Regulatory Filings
2020-08-17 English
NOTICE OF BOARD MEETING
Regulatory Filings
2020-08-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
Share Issue/Capital Change
2020-08-05 English
Voluntary Announcement - APG-115 completed dosing of the first patient in Phase Ib clinical study in China
Regulatory Filings
2020-07-22 English
Voluntary Announcement - APG-2575 Granted Orphan Drug Designation by the US FDA
Regulatory Filings
2020-07-15 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2020-07-15 English
CLOSING OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2020-07-15 English
2019 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2020-07-13 English
PLACING OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2020-07-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
Regulatory Filings
2020-07-06 English
Voluntary Announcement - Clinical Collaboration with MSD
Regulatory Filings
2020-07-06 English
Voluntary Announcement - Clinical Collaboration with Acerta Pharma, the Hematology Research and Development Center of Excellence of AstraZeneca
Regulatory Filings
2020-06-22 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 19, 2020
Declaration of Voting Results & Voting Rights Announcements
2020-06-19 English
Voluntary Announcement - Submission of New Drug Application for HQP1351 in China
Regulatory Filings
2020-06-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020
Regulatory Filings
2020-06-03 English
Voluntary Announcement - Latest Clinical Data of Apoptosis Targeting Drug Candidates was Presented at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Regulatory Filings
2020-05-31 English
Voluntary Announcement - HQP1351 Granted Fast Track Designation by the US FDA
Regulatory Filings
2020-05-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020
Share Issue/Capital Change
2020-05-06 English
Voluntary Announcement - HQP1351 Granted Orphan Drug Designation by the U.S. FDA
Regulatory Filings
2020-05-04 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2020-04-17 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 19, 2020
AGM Information
2020-04-17 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement
2020-04-17 English
ANNUAL REPORT 2019
Annual Report
2020-04-17 English
Voluntary Announcement - Approval for the Phase Ib/II Clinical Study of APG-2575 in China
Regulatory Filings
2020-04-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
Major Shareholding Notification
2020-04-06 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2019
Annual Report
2020-03-29 English
Voluntary Announcement - APG-2575 completed dosing of first patient in Phase Ib/II trial in the U.S.
Regulatory Filings
2020-03-23 English
NOTICE OF BOARD MEETING
Regulatory Filings
2020-03-12 English
VOLUNTARY ANNOUNCEMENT - Approvals Obtained in China and U.S. for Three Phase Ib/II Clinical Trials of APG-2575
Regulatory Filings
2020-03-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
Share Issue/Capital Change
2020-03-04 English
VOLUNTARY ANNOUNCEMENT - Approval of Phase Ib/II Clinical Trial of APG-1387 for the Treatment of Advanced Pancreatic Cancer in Combination with Chemotherapy in China
Regulatory Filings
2020-02-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020
Share Issue/Capital Change
2020-02-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
Regulatory Filings
2020-01-03 English